RMD
ResMed Inc.NYSE
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 8, 1:48 PM
    | Tue, Nov. 8, 1:48 PM
  • Tue, Oct. 25, 5:34 PM
    • ResMed (NYSE:RMD) fiscal Q1 results ($M): Revenues: 465.5 (+13.1%).
    • Net Income: 76.1 (-8.2%); Non-GAAP Net Income: 87.7 (+3.6%); EPS: 0.54 (-6.9%); Non-GAAP EPS: 0.62 (+5.1%); CF Ops: 86.2 (-30.8%).
    • No guidance given.
    • Revenues were 1.9% below consensus of $474.7M. Non-GAAP EPS was 3.1% short of consensus of $0.64.
    • Shares unchanged after hours.
    | Tue, Oct. 25, 5:34 PM
  • Tue, Oct. 25, 4:08 PM
    • ResMed (NYSE:RMD): FQ1 EPS of $0.62 misses by $0.02.
    • Revenue of $465.4M (+13.1% Y/Y) misses by $9.33M.
    • Press Release
    | Tue, Oct. 25, 4:08 PM
  • Mon, Oct. 24, 5:35 PM
    | Mon, Oct. 24, 5:35 PM | 20 Comments
  • Fri, Sep. 30, 8:05 AM
    • Resmed (NYSE:RMD) upgraded to Buy from Neutral by Bank of America. Price target raised to $89.00 (39% upside) from $71.50.
    • Incyte (NASDAQ:INCY) upgraded to Outperform from Market Perform by Raymond James.
    • Eli Lilly (NYSE:LLY) upgraded to Buy from Neutral by Goldman Sachs. Price target raised to $95 (19% upside) from $89.
    • Impax Laboratories (NASDAQ:IPXL) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $26 (10% upside) from $25.
    • Hologic (NASDAQ:HOLX) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $44 (15% upside) from $42.
    • BioDelivery Sciences International (NASDAQ:BDSI) upgraded to Buy from Neutral by Janney Montgomery Scott. Price target raised to $4.00 (47% upside) from $2.45.
    • Galectin Therapeutics (NASDAQ:GALT) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $1.50 (23% upside) from $8.00. Downgraded to Sell from Buy by Roth Capital. Price target lowered to $0.75 (39% downside risk) from $3.00.
    • Gilead Sciences (NASDAQ:GILD) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $94 (21% upside) from $112.
    • Mirna Therapeutics (NASDAQ:MIRN) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $2 (4% upside) from $6.
    | Fri, Sep. 30, 8:05 AM | 17 Comments
  • Fri, Aug. 26, 7:26 AM
    • Bayer AG (OTCPK:BAYRY) upgraded to Buy from Neutral by Citigroup.
    • Allscripts (NASDAQ:MDRX) upgraded to Outperform from Market Perform by Leerink Swann. Price target raised to $17 (32% upside) from $16.
    • Healthways (NASDAQ:HWAY) upgraded to Equal Weight from Underweight by Barclays. Price target raised to $27 (10% upside) from $12.
    • Cardiovascular Systems (NASDAQ:CSII) upgraded to Outperform from Market Perform by Leerink Swann. Price target is $30 (26% upside).
    • Allergan plc (NYSE:AGN) upgraded to Buy from Neutral by Mizuho Securities. Price target raised to $318 (35% upside) from $248.
    • Healthways (HWay) downgraded to Sell from Neutral by UBS. Price target raised to $22.50 (8% downside risk) from $19.
    • ResMed (NYSE:RMD) downgraded to Underperform from Hold by Jefferies. Price target lowered to $58 (15% downside risk) from $60.
    • Relypsa (NASDAQ:RLYP) downgraded to Hold from Buy by Stifel Nicolaus. Price target is $32 (0% upside).
    • Portola Pharmaceuticals (NASDAQ:PTLA) downgraded to Neutral from Buy by Citigroup. Price target lowered to $24 (21% upside) from $40.
    • Juniper Pharmaceuticals (NASDAQ:JNP) downgraded to Neutral from Buy by H.C. Wainwright. Price target is $6.75 (17% upside).
    | Fri, Aug. 26, 7:26 AM | 1 Comment
  • Thu, Jul. 28, 5:46 PM
    • ResMed (NYSE:RMD) declares $0.33/share quarterly dividend, 10% increase from prior dividend of $0.30.
    • Forward yield 2.01%
    • Payable Sept. 22; for shareholders of record Aug. 18; ex-div Aug. 16.
    | Thu, Jul. 28, 5:46 PM
  • Thu, Jul. 28, 4:10 PM
    • ResMed (NYSE:RMD): FQ4 EPS of $0.74 in-line.
    • Revenue of $518.65M (+14.5% Y/Y) beats by $4.68M.
    • Press Release
    | Thu, Jul. 28, 4:10 PM
  • Wed, Jul. 27, 5:35 PM
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Wed, Apr. 27, 10:45 AM
    • ResMed (RMD -7%) FQ3 results: Revenues: $453.9M (+7.4%); R&D Expense: $28.1M (+4.1%); SG&A: $119.4M (+2.7%); Operating Income: $104.3M (-1.5%); Net Income: $88.5M (-2.7%); EPS: $0.63 (-1.6%); Non-GAAP EPS: $0.68 (+4.6%); Quick Assets: $718.5M (+0.2%); CF Ops: $391.7M (+38.2%).
    • No guidance given.
    | Wed, Apr. 27, 10:45 AM
  • Tue, Apr. 26, 4:24 PM
    • ResMed (NYSE:RMD): FQ3 EPS of $0.68 misses by $0.01.
    • Revenue of $453.9M (+7.4% Y/Y) misses by $1.98M.
    | Tue, Apr. 26, 4:24 PM
  • Mon, Apr. 25, 5:35 PM
  • Mon, Feb. 22, 4:14 PM
    • ResMed (NYSE:RMD) acquires privately held Brighttree, a developer of business management and clinical cloud-based software applications for the post-acute care industry, for $800M in cash. ResMed will fund most of the purchase with debt.
    • The transaction will be immediately accretive to gross margins and non-GAAP EPS. It includes an estimated $300M from an anticipated future tax benefit, expected to positively affect ResMed's cash flow over 15 years.
    • Brightree booked $113M in sales and $43M in EBITDA last year.
    | Mon, Feb. 22, 4:14 PM | 2 Comments
  • Fri, Jan. 22, 8:24 AM
    • ResMed (RMD +0.61%) FQ2 results: Revenues: $454.5M (+7.4%); R&D Expense: $29M (-1.0%); SG&A: $118.2M (-3.5%); Operating Income: $108M (-1.0%); Net Income: $90.5M (-0.8%); EPS: $0.64 (unch); Non-GAAP EPS: $0.69 (+6.2%); Quick Assets: $658.8M (-8.1%).
    • No guidance given.
    | Fri, Jan. 22, 8:24 AM
  • Thu, Jan. 21, 4:13 PM
    • ResMed (NYSE:RMD): FQ2 EPS of $0.69 beats by $0.03.
    • Revenue of $454.5M (+7.5% Y/Y) beats by $8.25M.
    | Thu, Jan. 21, 4:13 PM